Moderna has begun experimenting with an injection directly into the heart to treat heart attack patients!

Moderna is developing an mRNA injection that is injected directly into the hearts of patients with heart attacks and heart failure.

The “vaccine” uses the same technology as the company’s flagship Covid vaccine and is intended for people weeks or months after a heart attack to help them recover.

It works by directing human heart cells to produce a hormone that improves blood flow and helps repair damaged heart muscles.

During a heart attack, muscle cells can begin to die and cannot regenerate. And almost one in five people who have a heart attack will be hospitalized for the second time within five years.

And this week, the drugmaker announced that the first patients had received the injection in a Phase I clinical trial.

“Now we have a very exciting program at the clinic where we are injecting mRNA into people’s hearts after a heart attack to grow new blood vessels to help revascularize the heart,” Stephane Bansel, CEO of Moderna, told Sky News. Australia in October A bit of sci-fi medicine, but that’s what I’m really interested in.”

And in its latest business update, Moderna announced this week that the first patients have received an injection, called mRNA-0184, as part of a Phase 1B clinical trial.

Patients have stable heart failure and the study will determine how safe the dose is and how well patients tolerate it, as well as improve the dose and frequency of administration.

Heart attacks occur when there is insufficient blood supply to the heart, and heart failure occurs when the heart cannot pump blood efficiently around the body.

Heart failure can occur after a heart attack if the muscle is severely damaged.

The new dose uses messenger RNA, which contains instructions for cells to make proteins.

DNA, stored in the nucleus of a cell, codes for genetic information for the production of proteins or hormones.

mRNA carries a copy of this genetic information from the nucleus to the cell’s cytoplasm, where it can be converted into proteins and hormones.

Moderna reported that the synthetic mRNA encodes relaxin, a naturally occurring hormone known to induce blood flow changes potentially beneficial for heart failure patients.

By injecting a synthetic mRNA encoding relaxin into the heart, the mRNA injection causes human cells to produce the hormone.

Moderna said: “The mRNA-0184 mRNA sequence was designed to cause the body to produce relaxin with an extended half-life with the aim of achieving sustained clinical benefit for patients with heart failure – this longer half-life could lead to more persistent effects than previous approaches. vessels and help in restoring blood flow through the arteries and veins.

Source: Daily Mail